免疫腫瘍薬の世界市場レポート 2025年

免疫腫瘍薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.4%で、1,531億6,000万米ドルに成長します。予測期間の成長は、免疫腫瘍学への投資の増加、がん治療のための免疫療法薬への注目の高まり、製品の革新に起因すると考えられます。予測期間の主な動向としては、特定の患者を治療するための個別化腫瘍治療薬の開発への投資、次世代生物製剤の開発への注力、抗体薬物複合体の開発への注力、AIソリューションへの投資、研究開発コストの削減と開発期間の短縮、イノベーションを後押ししカテゴリーリーダーシップを確立するための免疫腫瘍併用療法、イノベーションを後押ししカテゴリーリーダーシップを確立するためのカーT療法の導入などが挙げられます。

免疫腫瘍薬市場の成長は、世界のがん患者の増加によって促進されると予想されます。特に、米国がん協会が2022年1月に報告したところによると、米国だけでも190万人の新規がん診断と60万9,360人のがん関連死が予測されており、この問題の深刻さが浮き彫りになっています。肺がん、前立腺がん、腸がん、女性乳がんなど、世界的に最も罹患率の高いがん種を合わせると、新規がん罹患者全体の43％を占める。がんの罹患率が世界的に上昇するにつれて、今後数年間で免疫腫瘍薬に対する需要の急増が予想されます。

ヘルスケア支出の増加が免疫腫瘍薬市場の成長を促進すると予測されています。ヘルスケア支出とは、個人、組織、政府が特定の期間中にヘルスケア関連の製品やサービスに費やした総資金を指します。ヘルスケア支出の増加は、免疫腫瘍薬の開発、アクセシビリティ、使用を促進し、最終的にはがん治療成績の向上と革新的な治療法への患者のアクセス拡大につながります。例えば、英国の国家統計機関であるOffice for National Statisticsは、2022年に英国のヘルスケア支出が約3,548億8,000万米ドル（2,830億英ポンド）に達し、2021年と比較して名目で0.7％増加したと報告しています。このように、ヘルスケア支出の増加は、免疫腫瘍薬市場を前進させると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界免疫腫瘍薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の免疫腫瘍薬市場：成長率分析
• 世界の免疫腫瘍薬市場の実績：規模と成長, 2019-2024
• 世界の免疫腫瘍薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界免疫腫瘍薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の免疫腫瘍薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫チェックポイント阻害剤
• 免疫システム調節剤
• その他のモノクローナル抗体
• がんワクチン
• その他のタイプ
• 世界の免疫腫瘍薬市場治療用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 悪性黒色腫
• 肺がん
• 血液がん
• 腎細胞がん
• 前立腺がん
• 膀胱がん
• その他の治療用途
• 世界の免疫腫瘍薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 外来手術センター
• その他のエンドユーザー
• 世界の免疫腫瘍薬市場免疫チェックポイント阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PD-1阻害剤
• PD-L1阻害剤
• CTLA-4阻害剤
• 世界の免疫腫瘍薬市場免疫システム調節薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• サイトカイン
• インターフェロン
• コロニー刺激因子
• 世界の免疫腫瘍薬市場、その他のモノクローナル抗体のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的モノクローナル抗体
• 二重特異性抗体
• 世界の免疫腫瘍薬市場、がんワクチンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん予防ワクチン
• 治療用がんワクチン
• 世界の免疫腫瘍薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 養子細胞移植療法
• 腫瘍溶解性ウイルス療法

第7章 地域別・国別分析

• 世界の免疫腫瘍薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の免疫腫瘍薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 免疫腫瘍薬市場：競合情勢
• 免疫腫瘍薬市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca Plc
• Eli Lilly and Company
• Novartis International AG
• Pfizer Inc.
• Sanofi S.A.
• Arlak Biotech
• Apikos Pharma
• Kolaz biotech
• CStone Pharma
• CARsgen Therapeutics
• JW Therapeutics
• BeiGene
• Takeda Pharmaceuticals
• Astellas Pharma Inc
• Otsuka Pharmaceutical Co, Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 免疫腫瘍薬市場2029：新たな機会を提供する国
• 免疫腫瘍薬市場2029：新たな機会を提供するセグメント
• 免疫腫瘍薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Immuno-oncology drugs constitute a form of therapy or cancer treatment that utilizes drugs to either enhance or suppress the immune system, aiming to fortify the body's defenses against cancer, infections, and other disorders. These drugs leverage chemicals produced naturally by the body or synthesized in a laboratory to reinforce the immune system's capabilities, aiding the body in identifying and eliminating cancer cells.

The primary categories within the immuno-oncology drugs market include monoclonal antibodies, immune checkpoint inhibitors, immune system modulators, cancer vaccines, and others. Monoclonal antibodies are produced through the cloning of a single white blood cell, with each subsequent antibody traceable back to a single parent cell. Various therapeutic applications encompass melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer, and others. The application of immuno-oncology drugs spans sectors such as hospitals, clinics, ambulatory surgical centers, and cancer research institutes.

The immuno-oncology drugs market research report is one of a series of new reports from The Business Research Company that provides immuno-oncology drugs market statistics, including industry global market size, regional shares, competitors with an immuno-oncology drugs market share, detailed immuno-oncology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the immuno-oncology drugs industry. This immuno-oncology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immuno-oncology drugs market size has grown rapidly in recent years. It will grow from $94.16 billion in 2024 to $106.92 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to rise in the number of cancer cases, strong economic growth in emerging markets, increased healthcare expenditure, and an increase in pharmaceutical R&D expenditure.

The immuno-oncology drugs market size is expected to see strong growth in the next few years. It will grow to $153.16 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to increasing investment in immuno-oncology, rising focus on immunotherapy drugs for cancer treatment, product innovations. Major trends in the forecast period include investing in developing personalized oncology drugs to treat specific patients, focus efforts on the development of next-generation biologics, focus on the development of antibody-drug conjugates, invest in AI solutions, reduce R&D costs and save development time, immune-oncology combination therapies to boost innovation and establish category leadership, and implement car-t therapies to boost innovations and establish category leadership.

The growth of the immuno-oncology drugs market is expected to be fueled by the global increase in cancer cases. Notably, the American Cancer Society reported in January 2022 that the US alone is projected to witness 1.9 million new cancer diagnoses and 609,360 cancer-related deaths, highlighting the severity of the issue. The most prevalent types of cancer globally, including lung, prostate, bowel, and female breast cancer, collectively account for 43% of all new cancer cases. As cancer incidence rates rise globally, there is an anticipated surge in demand for immuno-oncology drugs in the coming years.

The rising healthcare expenditure is anticipated to drive the growth of the immuno-oncology drugs market. Healthcare expenditure refers to the total funds spent by individuals, organizations, or governments on healthcare-related products and services during a specific timeframe. An increase in healthcare expenditure can enhance the development, accessibility, and use of immuno-oncology drugs, ultimately leading to better cancer treatment outcomes and greater patient access to these innovative therapies. For example, in 2022, the Office for National Statistics, a UK-based national statistics organization, reported that UK healthcare expenditure reached around $354.88 billion (£283 billion), representing a nominal increase of 0.7% compared to 2021. Thus, rising healthcare expenditure is expected to propel the immuno-oncology drugs market forward.

Major companies in the immuno-oncology drugs market are forming collaborations to develop and commercialize a novel checkpoint antibody aimed at improving the effectiveness of cancer treatments. These strategic partnerships promote innovation through the exchange of interdisciplinary knowledge, facilitating the quicker development of combination therapies, personalized treatments, and new drug delivery systems. For example, in March 2023, BioNTech SE, a Germany-based company, joined forces with OncoC4 Inc., a US-based pharmaceutical firm, to co-develop and commercialize a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody candidate known as ONC-392. This collaboration seeks to enhance cancer treatment options across various solid tumor indications.

Leading companies in the immuno-oncology drugs market are prioritizing product development, such as Tebentafusp-TEBN, to broaden their product portfolios in cancer therapy. Tebentafusp-TEBN is a novel immuno-oncology drug that consists of a fusion protein combining a T-cell receptor (TCR) with an anti-CD3 antibody fragment. This unique construct is designed to target and engage T cells with cancer cells, especially melanoma, to activate the immune system's response against cancer. For instance, in January 2022, Immunocore, a UK-based biotechnology company, received Food and Drug Administration (FDA) approval for KIMMTRAK (Tebentafusp-TEBN) to treat HLA-A02:01-positive adult patients with unresectable or metastatic uveal melanoma. KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager that significantly extends overall survival in a randomized clinical trial, making it the first FDA-approved treatment for this condition.

In November 2023, AbbVie Inc., a US-based company, acquired ImmunoGen for $10.1 billion. This acquisition allows AbbVie to expand its portfolio by incorporating ImmunoGen's expertise in providing immuno-oncology drugs. ImmunoGen Inc. is a US-based company that specializes in immune checkpoint inhibitors.

Major companies operating in the immuno-oncology drugs market include F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co, Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals, Eurolab

North America was the largest region in the immuno-oncology drugs market in 2024. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the immuno-oncology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The immuno-oncology drugs market consists of sales of bevacizumab, alectinib, ibrutinib, imatinib, and palbociclib. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immuno-Oncology Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immuno-oncology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immuno-oncology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immuno-oncology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others
• 2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
• 3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Others
• Subsegments:
• 1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors
• 2) By Immune System Modulators: Cytokines; Interferons; Colony-Stimulating Factors
• 3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies; Bispecific Antibodies
• 4) By Cancer Vaccines: Preventive Cancer Vaccines; Therapeutic Cancer Vaccines
• 5) By Others: Adoptive Cell Transfer Therapies; Oncolytic Virus Therapies
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co.; Bristol-Myers Squibb Company; Amgen Inc; Johnson & Johnson
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Immuno-Oncology Drugs Market Characteristics

3. Immuno-Oncology Drugs Market Trends And Strategies

4. Immuno-Oncology Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Immuno-Oncology Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Immuno-Oncology Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Immuno-Oncology Drugs Market Growth Rate Analysis
• 5.4. Global Immuno-Oncology Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Immuno-Oncology Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Immuno-Oncology Drugs Total Addressable Market (TAM)

6. Immuno-Oncology Drugs Market Segmentation

• 6.1. Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Immune System Modulators
• Other Monoclonal Antibodies
• Cancer Vaccines
• Other Types
• 6.2. Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Melanoma
• Lung Cancer
• Blood Cancer
• Renal Cell Carcinoma
• Prostate Cancer
• Bladder Cancer
• Other Therapeutic Applications
• 6.3. Global Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Other End-Users
• 6.4. Global Immuno-Oncology Drugs Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-1 Inhibitors
• PD-L1 Inhibitors
• CTLA-4 Inhibitors
• 6.5. Global Immuno-Oncology Drugs Market, Sub-Segmentation Of Immune System Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytokines
• Interferons
• Colony-Stimulating Factors
• 6.6. Global Immuno-Oncology Drugs Market, Sub-Segmentation Of Other Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Monoclonal Antibodies
• Bispecific Antibodies
• 6.7. Global Immuno-Oncology Drugs Market, Sub-Segmentation Of Cancer Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines
• 6.8. Global Immuno-Oncology Drugs Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adoptive Cell Transfer Therapies
• Oncolytic Virus Therapies

7. Immuno-Oncology Drugs Market Regional And Country Analysis

• 7.1. Global Immuno-Oncology Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Immuno-Oncology Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Immuno-Oncology Drugs Market

• 8.1. Asia-Pacific Immuno-Oncology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Immuno-Oncology Drugs Market

• 9.1. China Immuno-Oncology Drugs Market Overview
• 9.2. China Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Immuno-Oncology Drugs Market

• 10.1. India Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Immuno-Oncology Drugs Market

• 11.1. Japan Immuno-Oncology Drugs Market Overview
• 11.2. Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Immuno-Oncology Drugs Market

• 12.1. Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Immuno-Oncology Drugs Market

• 13.1. Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Immuno-Oncology Drugs Market

• 14.1. South Korea Immuno-Oncology Drugs Market Overview
• 14.2. South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Immuno-Oncology Drugs Market

• 15.1. Western Europe Immuno-Oncology Drugs Market Overview
• 15.2. Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Immuno-Oncology Drugs Market

• 16.1. UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Immuno-Oncology Drugs Market

• 17.1. Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Immuno-Oncology Drugs Market

• 18.1. France Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Immuno-Oncology Drugs Market

• 19.1. Italy Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Immuno-Oncology Drugs Market

• 20.1. Spain Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Immuno-Oncology Drugs Market

• 21.1. Eastern Europe Immuno-Oncology Drugs Market Overview
• 21.2. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Immuno-Oncology Drugs Market

• 22.1. Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Immuno-Oncology Drugs Market

• 23.1. North America Immuno-Oncology Drugs Market Overview
• 23.2. North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Immuno-Oncology Drugs Market

• 24.1. USA Immuno-Oncology Drugs Market Overview
• 24.2. USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Immuno-Oncology Drugs Market

• 25.1. Canada Immuno-Oncology Drugs Market Overview
• 25.2. Canada Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Immuno-Oncology Drugs Market

• 26.1. South America Immuno-Oncology Drugs Market Overview
• 26.2. South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Immuno-Oncology Drugs Market

• 27.1. Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Immuno-Oncology Drugs Market

• 28.1. Middle East Immuno-Oncology Drugs Market Overview
• 28.2. Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Immuno-Oncology Drugs Market

• 29.1. Africa Immuno-Oncology Drugs Market Overview
• 29.2. Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Immuno-Oncology Drugs Market Competitive Landscape And Company Profiles

• 30.1. Immuno-Oncology Drugs Market Competitive Landscape
• 30.2. Immuno-Oncology Drugs Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Amgen Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

31. Immuno-Oncology Drugs Market Other Major And Innovative Companies

• 31.1. AstraZeneca Plc
• 31.2. Eli Lilly and Company
• 31.3. Novartis International AG
• 31.4. Pfizer Inc.
• 31.5. Sanofi S.A.
• 31.6. Arlak Biotech
• 31.7. Apikos Pharma
• 31.8. Kolaz biotech
• 31.9. CStone Pharma
• 31.10. CARsgen Therapeutics
• 31.11. JW Therapeutics
• 31.12. BeiGene
• 31.13. Takeda Pharmaceuticals
• 31.14. Astellas Pharma Inc
• 31.15. Otsuka Pharmaceutical Co, Ltd

32. Global Immuno-Oncology Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Immuno-Oncology Drugs Market

34. Recent Developments In The Immuno-Oncology Drugs Market

35. Immuno-Oncology Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Immuno-Oncology Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Immuno-Oncology Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Immuno-Oncology Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer